Alain Cohen-Solal

List of Publications by Year
in descending order

65 papers	3,181 citations	236925 25 h-index	161849 54 g-index

65 all docs	65 docs citations	65 times ranked	4017 citing authors

#	Article	IF	Citations
1	Iron deficiency in heart failure: why so frequent and which mechanisms?. European Heart Journal, 2022, 43, e35-e37.	2.2	3
2	Thromboembolism and bleeding in systemic amyloidosis: a review. ESC Heart Failure, 2022, 9, 11-20.	3.1	27
3	Education and certification on heart failure of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology. European Journal of Heart Failure, 2022, 24, 249-253.	7.1	6
4	Iron deficiency in heart failure patients: the French CARENFER prospective study. ESC Heart Failure, 2022, 9, 874-884.	3.1	22
5	Towards a Common Definition for the Diagnosis of Iron Deficiency in Chronic Inflammatory Diseases. Nutrients, 2022, 14, 1039.	4.1	11
6	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121008970.	3.9	8
7	Coronary Computed Tomography Angiography Analysis of Calcium Content to Identify Non-culprit Vulnerable Plaques in Patients With Acute Coronary Syndrome. Frontiers in Cardiovascular Medicine, 2022, 9, 876730.	2.4	5
8	Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action. Journal of Internal Medicine, 2022, 292, 542-556.	6.0	17
9	Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial?. JAMA Cardiology, 2022, , .	6.1	1
10	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. Journal of Clinical Medicine, 2022, 11, 2976.	2.4	5
11	Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2021, 28, 460-495.	1.8	388
12	Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 231-239.	7.1	26
13	Sacubitril/valsartan for the management of heart failure: A perspective viewpoint on current evidence. International Journal of Cardiology, 2021, 327, 138-145.	1.7	19
14	Characterization of nonâ€•response to cardiac resynchronization therapy by postâ€•procedural computed tomography. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 135-144.	1.2	6
15	Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology andÂTraining of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 83-91.	7.1	17
16	Diagnosis and Treatment of Iron Deficiency in Heart Failure: OFICSel study by the French Heart Failure Working Group. ESC Heart Failure, 2021, 8, 1509-1521.	3.1	14
17	Doxorubicinâ€•induced and trastuzumabâ€•induced cardiotoxicity in mice is not prevented by metoprolol. ESC Heart Failure, 2021, 8, 928-937.	3.1	11
18	Management of Immune Checkpoint Inhibitorâ€“Induced Myocarditis. JACC: CardioOncology, 2021, 3, 157-161.	4.0	22

#	Article	IF	Citations
19	The Impact of Patients With CardiacÂAmyloidosis in HFpEF Trials. JACC: Heart Failure, 2021, 9, 169-178.	4.1	39
20	Iron deficiency in pulmonary arterial hypertension: perspectives. Pulmonary Circulation, 2021, 11, 1-4.	1.7	5
21	Severe Myocardial Dysfunction after Non-Ischemic Cardiac Arrest: Effectiveness of Percutaneous Assist Devices. Journal of Clinical Medicine, 2021, 10, 3623.	2.4	1
22	Left Atrioventricular Coupling Index to Predict Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis. Frontiers in Cardiovascular Medicine, 2021, 8, 704611.	2.4	13
23	Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era. European Journal of Preventive Cardiology, 2021, 28, 541-557.	1.8	20
24	<scp>COVID</scp>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	7.1	32
25	Right ventricular function and iron deficiency in acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 406-414.	1.0	8
26	Is the glass half full or half empty after PARAGON-HF?. Cardiovascular Research, 2020, 116, e5-e7.	3.8	2
27	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>Cardioâ€Oncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>Cardioâ€Oncology Council of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2020, 22, 1966-1983.	7.1	184
28	Recommandations de la SociÃ©tÃ© franÃ§aise de rhumatologie pour la prise en charge de la gouttÂ: le traitement hypo-uricÃ©miant. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 332-341.	0.0	5
29	Delayed acute myocarditis and COVIDâ€19â€related multisystem inflammatory syndrome. ESC Heart Failure, 2020, 7, 4371-4376.	3.1	46
30	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>ociety. European Journal of Heart Failure, 2020,	7.1	364
31	All rise! Orthostatic hypotension in heart failure: reply. European Journal of Heart Failure, 2020, 22, 1742-1742.	7.1	0
32	The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions. European Heart Journal, 2020, 41, 1357-1364.	2.2	47
33	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation (<scp>HFA</scp>), the <scp>E</scp>uropean <scp>A</scp>ssociation of <scp>C</scp>ardiovascular <scp>I</scp>maging (<scp>EACVI</scp>) and the <scp>Cardioâ€Oncology C</scp>ouncil of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 1504-1524.	7.1	234
34	Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. European Journal of Heart Failure, 2020, 22, 1357-1365.	7.1	66
35	2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares. Joint Bone Spine, 2020, 87, 387-393.	1.6	17
36	2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine, 2020, 87, 395-404.	1.6	47

#	Article	IF	Citations
37	Recent advances in cardioâ€oncology: a report from the â€˜Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019â€™. ESC Heart Failure, 2019, 6, 1140-1148.	3.1	34
38	East Asia may have a better 1â€year survival following an acute heart failure episode compared with Europe: results from an international observational cohort. European Journal of Heart Failure, 2018, 20, 1071-1075.	7.1	13
39	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. European Journal of Heart Failure, 2018, 20, 1664-1672.	7.1	92
40	Ambulatory cardiac rehabilitation facilities should be present in every cardiology department. European Journal of Preventive Cardiology, 2018, 25, 1704-1706.	1.8	5
41	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the <scp>EDIFY</scp> randomized placeboâ€controlled trial. European Journal of Heart Failure, 2017, 19, 1495-1503.	7.1	154
42	RELAXâ€AHF, BLASTâ€AHF, TRUEâ€AHF, and other important truths in acute heart failure research. European Journal of Heart Failure, 2017, 19, 1355-1357.	7.1	9
43	Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Failure, 2017, 4, 499-506.	3.1	42
44	Precipitating factors and 90â€day outcome of acute heart failure: a report from the intercontinental <scp>GREAT</scp> registry. European Journal of Heart Failure, 2017, 19, 201-208.	7.1	126
45	Clinical benefits of natriuretic peptides and galectin-3 are maintained in old dyspnoeic patients. Archives of Gerontology and Geriatrics, 2017, 68, 33-38.	3.0	4
46	Baseline subendocardial viability ratio influences left ventricular systolic improvement with cardiac rehabilitation. Anatolian Journal of Cardiology, 2017, 17, 37-43.	0.9	9
47	The value of novel invasive hemodynamic parameters added to the TIMI risk score for short-term prognosis assessment in patients with ST segment elevation myocardial infarction. International Journal of Cardiology, 2016, 214, 235-240.	1.7	6
48	Management of acute heart failure in elderly patients. Archives of Cardiovascular Diseases, 2016, 109, 422-430.	1.6	28
49	Natriuretic peptides in addition to Zwolle score to enhance safe and early discharge after acute myocardial infarction: A prospective observational cohort study. International Journal of Cardiology, 2016, 215, 527-531.	1.7	10
50	Non-vitamin K antagonist oral anticoagulants and heart failure. Archives of Cardiovascular Diseases, 2016, 109, 641-650.	1.6	12
51	Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. European Journal of Heart Failure, 2015, 17, 1114-1123.	7.1	49
52	Effects of exercise on postexercise ventricularâ€“arterial coupling and pulsatile efficiency in patients with systolic dysfunction. European Journal of Clinical Investigation, 2015, 45, 1042-1051.	3.4	2
53	Effects of Physical Exercise on Cardiovascular Diseases: Biochemical, Cellular, and Organ Effects. BioMed Research International, 2015, 2015, 1-2.	1.9	4
54	Assessment of dyspnoea in the emergency department by numeric and visual scales: A pilot study. Anaesthesia, Critical Care & Pain Medicine, 2015, 34, 95-99.	1.4	8

#	Article	IF	Citations
55	Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly InhibitÂCirculating Neprilysin Activity inÂHeartÂFailure. JACC: Heart Failure, 2015, 3, 629-636.	4.1	72
56	Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure. International Journal of Cardiology, 2015, 199, 241-247.	1.7	44
57	Effects of Cardiopulmonary Exercise Rehabilitation on Left Ventricular Mechanical Efficiency and Ventriculaâ€Arterial Coupling in Patients With Systolic Heart Failure. Journal of the American Heart Association, 2015, 4, e002084.	3.7	16
58	Prognostic markers of acute decompensated heart failure: The emerging roles of cardiac biomarkers and prognostic scores. Archives of Cardiovascular Diseases, 2015, 108, 64-74.	1.6	32
59	Association between baseline cardiovascular mechanics and exercise capacity in patients with coronary artery disease. Anatolian Journal of Cardiology, 2015, 16, 608-613.	0.9	8
60	High prevalence of iron deficiency in patients with acute decompensated heart failure. European Journal of Heart Failure, 2014, 16, 984-991.	7.1	113
61	Diagnosis and treatment of iron deficiency in patients with heart failure: Expert position paper from French cardiologists. Archives of Cardiovascular Diseases, 2014, 107, 563-571.	1.6	27
62	Iron deficiency: an emerging therapeutic target in heart failure. Heart, 2014, 100, 1414-1420.	2.9	95
63	Lowered B-Type Natriuretic Peptide in Response to Levosimendan or Dobutamine Treatment Is Associated With Improved Survival in Patients With Severe Acutely Decompensated Heart Failure. Journal of the American College of Cardiology, 2009, 53, 2343-2348.	2.8	107
64	Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA studyâ˜†. European Journal of Heart Failure, 2006, 8, 697-705.	7.1	286
65	Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. Journal of Nuclear Medicine, 2005, 46, 1796-803.	5.0	36